WATCH: Overcoming obstacles in antibody patent protection
Michael Shuster, Partner at Goodwin Law, moderates a discussion with Guy Birkenmeier, Senior IP Counsel at New England Biolabs; Michael Penn, Vice President of Intellectual Property at BlueRock Therapeutics; and Ben Doranz, President and CEO of Integral Molecular.The panel considers effective approaches to overcoming genus claim limitations, navigating subject matter eligibility concerns, and addressing an increasingly complex obviousness landscape driven by AI and computational tools. They share actionable insights on drafting applications that can withstand rigorous PTAB scrutiny and inconsistent examination standards.The conversation also broadens to international strategies, examining how other jurisdictions are handling antibody patent applications and offering guidance on strengthening claims during prosecution to survive enablement and written description challenges.
